|
Nephroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Introduction of a stabilizing β-catenin mutation restricted to the kidney is sufficient to induce primitive renal epithelial tumors; however, when compounded with activation of K-RAS, the mice develop large, bilateral, metastatic, multifocal primitive renal epithelial tumors that have the histologic and staining characteristics of the epithelial component of human WT.
|
21983638 |
2011 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations were detected in previously described WT "hot spots" (e.g., WT1 and CTNNB1) as well as novel loci that may be unique to the Iraqi population.
|
30155617 |
2018 |
|
Nephroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, reduced levels of β-catenin, MYC, and WT1 are molecular markers for the efficacy of HDACi.
|
31561534 |
2019 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abnormalities of WT1, WTX and CTNNB1, and loss of IGF2 imprinting (LOI) were detected in 31.6%, 22.8%, 26.3%, and 21.1% of the 114 WTs, respectively.
|
22409817 |
2012 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The 17.94 cell line contained a TP53 mutation, consistent with the anaplastic histology of the original tumor, but lacked mutations in WT1, WTX, or CTNNB1, which are the other genes involved in WT pathogenesis.
|
22749038 |
2012 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytoplasmic beta-catenin accumulation was demonstrated in two papillary carcinomas, one neuroblastoma-associated carcinoma, and two carcinomas arising from nephroblastoma.
|
17873895 |
2007 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
GS expression was not observed in CTNNB1-mutated nephroblastoma.
|
21237236 |
2011 |
|
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To assess the relationship of WT1 mutations vis-à-vis beta-catenin mutations in Wilms tumor, we analyzed 153 primary tumors, and 21 of 153 (14%) carried beta-catenin mutations.
|
11103785 |
2000 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
β-catenin, an important gene in the Wnt canonical pathway, was downregulated after WT1 RNAi.
|
25310451 |
2014 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other genes frequently altered somatically in subsets of WT are CTNNB1 and WTX; both genes influence the Wnt signalling pathway.
|
22461142 |
2013 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Microsatellite analysis of APC and immunoexpression of beta catenin did not provide significant pathological or prognostic information in this cohort of nephroblastomas.
|
15623481 |
2005 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wilm's tumor 1 (WT1) has been found to have opposing roles with β-catenin in podocyte biology.
|
28315733 |
2017 |
|
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemistry was also performed to investigate how the mutations in beta-catenin alter the localisation in Wilms tumour development.
|
17172473 |
2007 |
|
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Wilms' tumor (WT), the most common pediatric renal malignancy, is associated with mutations in several well-characterized genes, most notably WT1, CTNNB1, WTX, and TP53.
|
20332316 |
2010 |
|
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genes identified as being mutated in Wilms' tumour include TP53, a classic tumour suppressor gene (TSG); CTNNB1 (encoding β-catenin), a classic oncogene; WTX, which accumulating data indicate is a TSG; and WT1, which is inactivated in some Wilms' tumours, similar to a TSG.
|
21248786 |
2011 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
One blastema-type nephroblastoma showed nuclear localisation of β-catenin in conjunction with LOH of the APC gene.
|
22081130 |
2011 |
|
Nephroblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study has analysed the intracellular levels and subcellular distribution of beta-catenin protein in 36 primary Wilms' tumour specimens and has correlated these results with the mutational status of the beta-catenin gene.
|
12474228 |
2003 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on characterization of both genomic and expression status of WT1 and CTNNB1 (beta-catenin) in a series of 60 Wilms tumor samples, combined with genome-wide expression profiling of these tumors, normal mature and fetal kidney controls, we show that WT1/beta-catenin expression was a better classifier than WT1/CTNNB1 mutations.
|
19530245 |
2009 |
|
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Canonical WNT signalling determines lineage specificity in Wilms tumour.
|
19137020 |
2009 |
|
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GS expression was not observed in CTNNB1-mutated nephroblastoma.
|
21237236 |
2011 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
|
28825729 |
2017 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin.
|
14666652 |
2004 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
At least three different pathways are involved in Wilms tumor; this review represents the outcome of the workshop discussion on the WNT/β-catenin pathway in Wilms tumorigenesis.
|
24258344 |
2013 |
|
Nephroblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Implication of beta-catenin mutations in WT was investigated in 24 tumors collected from 20 WT patients.
|
12239584 |
2002 |
|
Nephroblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, FZD7-resistant WT in which no cell death was induced showed a different intra-cellular route of the Ab-FZD7 complex compared with sensitive tumors and accumulation of β-catenin.
|
21472018 |
2011 |